The Open Question Under Johnson & Johnson Stock’s Price

Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The lineup includes ICOTYDE, an oral treatment for plaque psoriasis. The company has yet to disclose sales figures for the medication. How much the drug can ultimately add to J&J remains an open question. Anyone purchasing shares today takes on that unknown before the answer is in.

J&J Expects ICOTYDE To Become A Major Drug

During the third-quarter 2026 earnings call on October 13, 2026, J&J was asked if it sees ICOTYDE as a $10 billion-plus asset. Management responded that the drug is off to a great start. Executives foresee ICOTYDE becoming one of the biggest assets within Innovative Medicine, J&J's medicines business. Outside the company, Bank of America raised its peak sales estimate for ICOTYDE to $4.5 billion, from $2.4 billion, in late September 2026.

J&J points to clinical data to support its own outlook. The company published two-year trial results on October 9, 2026. Nearly three-quarters of the participating adults and adolescents with plaque psoriasis achieved clear or almost clear skin.

Medicines Bring In Nearly Two-Thirds Of J&J's Sales

The Innovative Medicine unit brought in $60.4 billion in fiscal 2025, representing 64% of total revenue for J&J that year. Segment sales climbed 7.9% in the third quarter of 2026, compared with a 6% growth rate for the broader company. The MedTech division grew 2.5%, a figure management said fell short of its expectations.

Inside the medicines business, older and newer treatments are moving in opposite directions. Sales of STELARA fell 54% as biosimilar copies competed with it, management noted. TREMFYA grew 68.2%, helped by its launch in inflammatory bowel disease, and CAPLYTA grew 66.1%. Growth in the largest business at J&J appears to come from newer drugs like these. The company is now counting on ICOTYDE to follow suit.

How Is ICOTYDE's Launch Going For J&J?

Management stated that ICOTYDE continues to outpace recent product launches from competitors. Executives also noted all national plans now broadly cover the drug. Neither statement reveals how much money the medication actually earns for J&J.

When Will J&J Start Reporting ICOTYDE's Sales?

Management expressed confidence that J&J will begin disclosing sales numbers for ICOTYDE in 2027. That initial financial report is the one to watch. That first figure will finally measure what the drug earns, rather than merely tracking how fast its launch is moving.

How To Act On JNJ?

Now you know JNJ better. And that's our purpose: to make you informed before you invest your money. However, making a bet on a single stock carries its own risks.

There is a smarter choice. Since its inception, the Trefis High Quality (HQ) Portfolio has beaten the benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking.

If you'd rather act on JNJ itself:

See Your Next Steps On JNJ